WuXi AppTec Co

WuXi AppTec Co ROE

The Return on Equity (ROE) of WuXi AppTec Co (603259.SS) as of Nov 12, 2026 is 24.07 %. In the previous year, Return on Equity (ROE) was 16.12 % — a change of 49.35% (higher).

ROE

24.07 %

YoY

49.35%

Last updated:

In 2025, WuXi AppTec Co's return on equity (ROE) was 24.07 %, a 49.35% increase from the 16.12 % ROE in the previous year.

The WuXi AppTec Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
12.80 CNY
Jan 1, 2019
10.71 CNY
Jan 1, 2020
9.11 CNY
Jan 1, 2021
13.24 CNY
Jan 1, 2022
18.92 CNY
Jan 1, 2023
17.43 CNY
Jan 1, 2024
16.12 CNY
Jan 1, 2025
24.07 CNY
The WuXi AppTec Co ROE history
YEARROEYoY
24.07 %+49.35%
16.12 %-7.52%
17.43 %-7.87%
18.92 %+42.86%
13.24 %+45.36%
9.11 %-14.96%
10.71 %-16.31%
12.80 %-33.84%
19.35 %+10.51%
17.51 %+68.95%
10.36 %-41.56%
17.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WuXi AppTec Co Stock analysis

What does WuXi AppTec Co do? WuXi AppTec Co Ltd is a Chinese company that was founded in 2000 and specializes in the development of customer-oriented services in the pharmaceutical research and in vitro diagnostics sectors. The company operates multiple facilities in China, the USA, Europe, and Singapore. The business model of WuXi AppTec is based on the development and provision of services to meet the needs of customers worldwide. This includes activities such as bioanalysis, chemical development, drug manufacturing, and regulatory compliance and quality assurance services. In terms of various industries, the company is divided into three main divisions. The Chemical Division specializes in chemical development and drug manufacturing. The team has expertise in synthesizing complex molecules, scaling up for clinical trials, manufacturing bulk products for commercial use, and supplying APIs for formulation. The company has state-of-the-art facilities and technologies to ensure high product quality and fast production time. The Medical Device Division provides in vitro diagnostics for the global market to enable rapid and reliable medical diagnosis. The focus is on developing innovative technologies and applications in the fields of oncology, infectious diseases, and neurology. The company has many partnerships with leading in vitro diagnostics companies to enhance the quality and reach of products and services. The Biological Division specializes in the development of biopharmaceutical products and services. This includes the development of monoclonal antibodies to the production of recombinant proteins. The services include process development, manufacturing, characterization, and analysis of biological products. WuXi AppTec is at the forefront of technology and provides its customers with state-of-the-art facilities and technologies. In addition to the aforementioned services, WuXi AppTec also offers solutions in the field of bioanalytics, supporting the development of analytical methods and drug validation. The company has also recently expanded into other areas, including the acquisition of NextCODE Health, a firm specializing in genetic diagnostics and analysis tools. The company operates internationally and collaborates with a wide range of customers in the pharmaceutical and biotech sectors. It is also part of a global network of companies focusing on therapeutic technologies, clinical trials, drug marketing, and other aspects of the pharmaceutical industry. WuXi AppTec aims to provide its customers with high-quality products and services that are scientifically sound and effective. The company invests in research and development to provide its customers with the latest technologies and discoveries. WuXi AppTec Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding WuXi AppTec Co's Return on Equity (ROE)

WuXi AppTec Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing WuXi AppTec Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

WuXi AppTec Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in WuXi AppTec Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about WuXi AppTec Co stock

Return on Equity (ROE) of WuXi AppTec Co is 24.07 % in 2025.

Return on Equity (ROE) of WuXi AppTec Co changed from 16.12 % to 24.07 %, representing a 49.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) WuXi AppTec Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s WuXi AppTec Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — WuXi AppTec Co

All Key Metrics — WuXi AppTec Co